Skip to content
Flyout Menu
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    • Discovery
      • CADD & Structural Biology
      • Compound Management
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vitro Biology
      • In Vivo Pharmacology
      • Integrated Drug Discovery (IDD)
      • Safety & Toxicology
      • Synthetic & Medicinal Chemistry
    • Drug Substance Development
      • Analytical Development
      • Developability & Pre-Formulation
      • Particle Science & Engineering
      • Process Development
      • Process Engineering
      • Discovery Process Chemistry
    • Drug Substance Manufacturing
      • Engineering Technologies
      • Infrastructure
      • Product Types
    • New Modalities
      • Antibody–Drug Conjugates
      • Lipids
      • Oligos
      • Peptides
    • Formulations
      • Clinical Formulation Supplies
      • New Chemical Entity (NCE) formulation development
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Newsroom – Blogs
    • Newsroom – Case Studies
  • Investors
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
  • Our Capabilities
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
  • Our Capabilities
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    Main Menu
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    Main Menu
    • Discovery
      • Integrated Drug Discovery (IDD)
      • CADD & Structural Biology
      • Synthetic & Medicinal Chemistry
      • In Vitro Biology
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vivo Pharmacology
      • Safety & Toxicology
      • Compound Management
    • Drug Substance Development
      • Discovery Process Chemistry
      • Process Development
      • Analytical Development
      • Process Engineering
      • Particle Science & Engineering
      • Developability & Pre-Formulation
    • Drug Substance Manufacturing
      • Product Types
      • Infrastructure
      • Engineering Technologies
    • Formulations
      • New Chemical Entity (NCE) formulation development
      • Clinical Formulation Supplies
    • New Modalities
      • Antibody–Drug Conjugates
      • Peptides
      • Oligos
  • Sustainability
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    Main Menu
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    Main Menu
    • Discovery
      • Integrated Drug Discovery (IDD)
      • CADD & Structural Biology
      • Synthetic & Medicinal Chemistry
      • In Vitro Biology
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vivo Pharmacology
      • Safety & Toxicology
      • Compound Management
    • Drug Substance Development
      • Discovery Process Chemistry
      • Process Development
      • Analytical Development
      • Process Engineering
      • Particle Science & Engineering
      • Developability & Pre-Formulation
    • Drug Substance Manufacturing
      • Product Types
      • Infrastructure
      • Engineering Technologies
    • Formulations
      • New Chemical Entity (NCE) formulation development
      • Clinical Formulation Supplies
    • New Modalities
      • Antibody–Drug Conjugates
      • Peptides
      • Oligos
  • Sustainability
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us

From Commitment to Action: Sai Life Sciences makes strides towards a greener earth

On the World Environment Day, we reflect on the efforts we’ve taken towards sustainability. A year ago, on June 5th, 2023, Sai Life Sciences renewed its Sustainable Development Goals (SDGs), charting a roadmap to achieve specific environmental, social, and governance (ESG) targets by FY27, with FY22 as the baseline year. Three of these SDGs pertain to the environment including reducing water consumption, cutting down on GHG emissions, boosting the usage of clean energy, and decreasing hazardous waste generation through co-processing and alternate reuse. Here's how our journey has unfolded in each of these areas:

Reducing water consumption:
Image: https://www.dropbox.com/scl/fi/ef1ovya5sricuxxfzkifi/From-Commitment-to-Action-Sai-Life-Sciences-makes-strides-towards-a-greener-earth-Reducing-water-consumption.png?rlkey=rhse0v6dchtxtfp9vr9er460h&st=5osir1re&dl=0

Sai Life Sciences has implemented various measures to reduce specific water consumption by 25% by FY27. Water is crucial in our production processes, and we've deployed smart solutions to minimize its usage. For example, we employ a spray ball system to clean reactors, effectively removing residues or contaminants while using less water compared to traditional methods. Similarly, high-pressure pumps for descaling are utilized, unleashing water at a controlled, elevated pressure to effectively remove scale buildup without excessive usage. Complementing these cleaning systems, sensor-equipped taps and pressure compensating aerators ensure water is used only, when necessary, thus minimizing waste. In addition to judicious water use, we focus on treating process effluents and utilizing treated wastewater for cooling tower backup, significantly reducing freshwater consumption. As we expand our capacity to treat and reuse water resources, we've also adopted rainwater collection and treatment systems and doubled our rainwater utilization in FY24 compared to FY23. By capturing and treating rainwater, we not only reduce our reliance on freshwater sources but also contribute to local ecosystem conservation efforts.

Cutting down on GHG emissions and adopting Renewable sources:
Image: https://www.dropbox.com/scl/fi/4chju4n28gqnn0y39n6c4/From-Commitment-to-Action-Sai-Life-Sciences-makes-strides-towards-a-greener-earth-Cutting-down-on-GHG-emissions-and-adopting-Renewable-sources.png?rlkey=mqtrikv1rkxr331prtn9w0p1l&st=zp6c43fb&dl=0

In order to reduce specific greenhouse gas emissions by 30% and replace 70% of our energy requirement with renewable sources, Sai Life Sciences has made significant strides. At the organization level, 50% of our energy needs are met by renewable sources. At our Bidar facility, 89% of our energy needs are met through clean energy, primarily solar and wind power. By harnessing abundant natural resources, we're accelerating our transition to clean and sustainable energy solutions, minimizing our reliance on fossil fuels and reducing our carbon footprint.

In our ongoing efforts to reduce carbon emissions and promote eco-friendly practices, Sai Life Sciences has introduced electric vehicles for interim material transfer.

In the area of energy-saving initiatives, implementing solutions like flash jet pumps in our Multiple Effect Evaporator (MEE) plant allows us to recover steam and condensate, maintaining optimal temperatures while conserving energy and resources. Similarly, we've replaced conventional CFL lights with energy-efficient LED alternatives, resulting in a considerable reduction in energy consumption, reinforcing our commitment to sustainability.

Managing Hazardous Waste:

We have been working towards reducing specific hazardous waste generation by 10% and recycling 90% of hazardous waste through co-processing and alternate reuse. We've ensured 100% disposal of hazardous waste to cement industries for co-processing, where it's utilized as alternate fuel or raw material. Embracing the concept of circularity, we minimize waste generation and reduce reliance on conventional fuels like coal.

Waste Minimization and Management
Image: https://www.dropbox.com/scl/fi/bquzrjj0nnq8fg8wi6hgm/From-Commitment-to-Action-Sai-Life-Sciences-makes-strides-towards-a-greener-earth-Waste-Minimization-and-Management.png?rlkey=daotcdnih2kwa4afb4hgv2aji&st=mr09wkaw&dl=0

As Sai Life Sciences prepares to mark another World Environment Day, our journey exemplifies dedication and commitment to sustainable practices, laying a foundation for a greener, more environmentally conscious future.

  • Sai Editorial
  • 5 Jun 2024
Link X-twitter Facebook Linkedin

Related Articles

  • Admin
  • - 3 Jun 2026

HTE: Unlocking the Potential of a Powerful Tool in Drug Discovery and Development

As an enabling technology, High Throughput Experimentation (HTE) has paved the way for the execution of large, parallel sets of experiments […]

  • Admin
  • - 13 May 2026

Dhruva – Intelligent Process Flow & Risk Evaluation Platform

Dhruva is our in-house digital application developed to automate Process Flow Diagrams (PFDs) and proactively identify potential risks associated with […]

  • Admin
  • - 13 May 2026

Contribution to ISPE Good Practice Guide: Technology Transfer

Sai Life Sciences contributed a case study to the International Society for Pharmaceutical Engineering (ISPE) Good Practice Guide: Technology Transfer […]

1 / 41234

DS-7, IKP Knowledge Park,
Turkapally Village, Shameerpet Mandal,
Medchal-Malkajgiri District-500078,
Telangana, India

Company
Main Menu
  • About Us
  • Investors
  • Careers
  • Contact us
Our Capabilities
Main Menu
  • Discovery
  • Drug Substance Development
  • Drug Substance Manufacturing
  • Formulations
  • New Modalities
Knowledge Hub
Main Menu
  • News
  • Blogs
  • Case Studies
Legal
Main Menu
  • Corporate Policies
  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions

© 2026 Sai Life Sciences All rights reserved.

Facebook-f Instagram Linkedin-in X-twitter Youtube